AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 55 filers reported holding AKERO THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,369,350 | +40.7% | 115,000 | -71.5% | 0.30% | +4.2% |
| Q2 2022 | $3,816,000 | -33.4% | 403,787 | 0.0% | 0.29% | -34.3% |
| Q1 2022 | $5,730,000 | -32.9% | 403,787 | 0.0% | 0.44% | -13.4% |
| Q4 2021 | $8,540,000 | -36.3% | 403,787 | -32.7% | 0.51% | -6.8% |
| Q3 2021 | $13,410,000 | -9.9% | 600,000 | 0.0% | 0.54% | +7.7% |
| Q2 2021 | $14,886,000 | -30.9% | 600,000 | -19.2% | 0.51% | +5.4% |
| Q1 2021 | $21,541,000 | +12.4% | 742,549 | 0.0% | 0.48% | +5.3% |
| Q4 2020 | $19,158,000 | -27.6% | 742,549 | -13.6% | 0.46% | -55.2% |
| Q3 2020 | $26,466,000 | +79.2% | 859,550 | +45.1% | 1.02% | +80.8% |
| Q2 2020 | $14,766,000 | +8.4% | 592,539 | -7.8% | 0.56% | -11.1% |
| Q1 2020 | $13,622,000 | -17.1% | 642,539 | -13.2% | 0.63% | -3.5% |
| Q4 2019 | $16,438,000 | -2.4% | 740,621 | 0.0% | 0.66% | -36.1% |
| Q3 2019 | $16,849,000 | +14.6% | 740,621 | -3.5% | 1.03% | +21.4% |
| Q2 2019 | $14,704,000 | – | 767,842 | – | 0.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |